Acadia Pharmaceuticals (ACAD) FCF Margin (2010 - 2026)
Acadia Pharmaceuticals (ACAD) recorded quarterly FCF Margin of 10.73% in Q1 2026, up 157.79% quarter-over-quarter from 18.57% in Q4 2025, and up 241.0% on a YoY basis from 3.15% in Q1 2025.
Acadia Pharmaceuticals (ACAD) FCF Margin (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' FCF Margin history runs 17 years deep, the most recent figure standing at 10.73% for Q1 2026.
- In Q1 2026, FCF Margin rose 241.0% year-over-year to 10.73%; the TTM figure through Mar 2026 stood at 10.37% (down 453.0% YoY), while the FY2025 annual figure was 9.81%, down 660.0% from the prior year.
- FCF Margin was 10.73% for Q1 2026 at Acadia Pharmaceuticals, up from 18.57% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 36.96% in Q4 2023 to a low of 66.1% in Q1 2022.
- Historically, FCF Margin has averaged 1.25% across 5 years, with a median of 8.32% in 2025.
- The sharpest annual moves came in 2023 and 2025: FCF Margin jumped 5444 bps in 2023, then sank 3395 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 17.48% in 2022, then jumped by 311 bps to 36.96% in 2023, then tumbled by 58 bps to 15.38% in 2024, then tumbled by 221 bps to 18.57% in 2025, then soared by 158 bps to 10.73% in 2026.
- The last three FCF Margin figures came in at 10.73% (Q1 2026), 18.57% (Q4 2025), and 26.52% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Acadia Pharmaceuticals | 3.68 Bn | 2.83 Bn | 243.27 Mn | 10.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.73% |
| Dec 31, 2025 | -18.57% |
| Sep 30, 2025 | 26.52% |
| Jun 30, 2025 | 24.06% |
| Mar 31, 2025 | 8.32% |
| Dec 31, 2024 | 15.38% |
| Sep 30, 2024 | 25.23% |
| Jun 30, 2024 | 10.34% |
| Mar 31, 2024 | 14.13% |
| Dec 31, 2023 | 36.96% |
| Sep 30, 2023 | -27.85% |
| Jun 30, 2023 | 4.96% |
| Mar 31, 2023 | -15.14% |
| Dec 31, 2022 | -17.48% |
| Sep 30, 2022 | -0.56% |
| Jun 30, 2022 | -9.75% |
| Mar 31, 2022 | -66.10% |
| Dec 31, 2021 | -17.68% |
| Sep 30, 2021 | -12.97% |
| Jun 30, 2021 | -22.02% |